ESR1 and neoplasm: Additionally, Feng et al. demonstrated that miR-339-5p is integrated into estrogen-regulated pathways through the MAFG-AS1/miR-339-5p/CDK2 axis, contributing to tumor progression and endocrine resistance in estrogen receptor–positive breast cancer22.